Rhythm Pharmaceuticals, Inc. (RYTM) shares are rising on Tuesday morning trade announces phase 2 positive proof-of-concept data for Setmelanotide in additional MC4R Pathway deficiency-related obesities.
Currently, shares are at $41.06, up 5.00 percent from the previous close of $39.19 on a volume of 500,303.
For the 52-week period, the shares have traded in a range of $12.99 -$43.23 on average volume of 390,353.
For comments and feedback contact: editorial@rttnews.com
